AI in Bronchoscopy Market Size, Share, and Industry Analysis, By Component (Hardware/ Devices and Software & Services), By Deployment (Cloud-Based, On Premise, and Hybrid), By Technology (Computer Vision, Machine Learning & Deep Learning, and Others), By Application (Navigation & Guidance, Biopsy Targeting & Lesion Detection, Real-time Anatomical Mapping, Performance Assessment & Training, and Others), By End User (Hospitals & ASCs, Specialty Clinics, Academic & Research Institutes, and Others), and Regional Forecast till 2034

The AI in bronchoscopy market size was valued at USD 0.16 billion in 2025. The market is projected to grow from USD 0.20 billion in 2026 to USD 1.70 billion by 2034, exhibiting a CAGR of 30.75% during the forecast period.

The AI in bronchoscopy market is poised for significant growth over the forecast period, driven by increasing digitalization and the adoption of AI tools in healthcare. These AI tools in bronchoscopy help overcome numerous limitations of traditional methods by providing real-time route planning and navigation guidancee during biopsies. They help healthcare providers to diagnose lung cancer earlier and more accurately, especially for small, peripheral lung nodules that are harder to reach with conventional bronchoscopy. Clinicians are increasingly in need of bronchoscopy systems that can navigate deeper, compensate for CT-to-body differences, and confirm targeting in real time. AI tools offer these solutions, increasing demand and driving market growth.

 Additionally, innovative product launches by key companies integrating advanced technologies determine the market's growth potential.

• For instance, in April 2024, Body Vision Medical launched a software update for its LungVision advanced navigation and real-time imaging platform. LungVision v2.27 introduced Body Vision's latest AI Tomo imaging algorithm, with a larger field of view, improving the reach and fidelity of virtual bronchoscopy in peripheral airways. Such developments boost market growth.

Furthermore, funding initiatives, technological advancements, and key mergers and partnerships by major companies strengthen their market position and support the overall market growth.

AI in Bronchoscopy Market Driver

Increasing Lung Cancer Screening Programs to Expand the Addressable Pool for AI-Assisted Bronchoscopy Drives Market Growth

One of the principal factors driving market growth is the expansion of lung cancer screening programs, leading to more early-stage diagnoses. As the volume of lung cancer screening programs increases, resulting in more screen-detected nodules, hospitals face pressure for rapid diagnoses. These factors elevate demand for AI in bronchoscopy to reliably reach small, peripheral lesions. AI-enabled navigation and real-time mapping, and targeting support help clinicians localize lesions more consistently and improve workflow efficiency. Screening scale-up also pushes more community and mid-tier centers to build lung nodule pathways, creating a larger install base for AI bronchoscopy software tied to navigation and robotic platforms. To commercialize this market potential, key companies are participating in strategic collaborations to advance technology.

• For instance, in January 2026, Bristol Myers Squibb collaborated with Microsoft to advance AI-driven early detection of lung cancer, aimed at expanding early detection workflows and access, and supporting upstream growth in screened populations that feed AI-assisted diagnostic pathways.

Download Free sample to learn more about this report.

For instance, in 2026, the American Cancer Society estimated that 110,910 new cancer cases would occur. Among lung cancers, small cell lung carcinoma (SCLC) accounted for 13%, and non-small cell lung carcinoma (NSCLC) accounted for about 77%. The increasing prevalence of lung cancer is driving demand for AI in bronchoscopy in cancer research.

AI in Bronchoscopy Market Restraint

Shortage of Trained Interventional Pulmonologists to Constrain Procedure Growth and Hamper Market Growth

One of the principal factors restraining the market is the shortage of trained interventional pulmonologists and bronchoscopy-capable teams. This shortage directly limits the efficiency with which hospitals can scale AI-enabled bronchoscopy. Even when the technology is available, when staffing is tight, hospitals prioritize urgent care delivery over adding new advanced workflows. Also, fewer specialists result in lower procedure capacity, longer waiting lists, and slower site onboarding/training for AI navigation or robotic bronchoscopy programs. This reduces utilization of installed systems, weakens the ROI case for new purchases, and can delay adoption and adversely affect market growth.

• For instance, in December 2025, in the US, HRSA's Physician Workforce projections (2023–2038) estimated a large overall physician shortfall by 2038, reinforcing the broader supply constraint affecting specialty service capacity.

AI in Bronchoscopy Market Opportunity

Expansion of Robotic-Assisted Bronchoscopy Programs in Mid-Tier Hospitals Creates a Major Growth Opportunity

A key factor offering significant growth opportunities for the market is the increasing adoption of robotic-assisted bronchoscopy programs. As robotic-assisted bronchoscopy moves beyond top-tier institutions into mid-tier hospitals, the addressable market expands, offering opportunities to bring advanced lung nodule biopsy in-house. When these hospitals offer higher-precision peripheral nodule access, they can capture more procedure volume, reduce patient leakage, and shorten time-to-diagnosis, thereby strengthening their business case. These factors collectively create a significant growth opportunity, as each new program typically requires navigation software, imaging integration, training services, and ongoing upgrades. These tools also generate recurring revenue and facilitate faster market expansion.

Underscoring these expanded applications, key companies are focusing on novel product launches, simultaneously seeking regulatory approval to capitalize on the growth potential.  

• For instance, in March 2025, Johnson & Johnson MedTech received 510(k) clearance from the U.S. FDA for MONARCH QUEST, highlighting AI-powered algorithms and imaging integration capabilities that support broader scaling of robotic bronchoscopy programs.

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Advancements in AI in Bronchoscopy
• Prevalence of Key Diseases, By Key Regions, 2025
• Key Industry Developments (Strategic Partnerships, Collaborations, Acquisitions, and Mergers)
• New Product Launches, By Key Players
• Key Start Ups, By Key Regions

Analysis by Component

Based on the component, the global AI in bronchoscopy market is segmented into hardware/ devices and software & services.

The hardware/devices segment is estimated to hold a leading share. AI in bronchoscopy is typically integrated into high-value procedural platforms, such as robotic bronchoscopy, navigation systems, and imaging-enabled suites. Hospitals must first invest in the physical system to enable advanced peripheral lung access; hardware accounts for the largest share of upfront spend. Once hardware is installed, software and services are added and grow over time, but the initial buying decision is typically anchored in the device platform and its clinical capabilities. New product launches with innovative features in the software segment to reinforce segment dominance.  

• For instance, in November 2023, HCA UK became the first to offer the Ion Endoluminal System for robotic-assisted lung biopsy—illustrating the high-value platform-led purchasing pattern. Such developments are expected to lead to segmental growth.

Analysis by Deployment

Based on deployment, the global AI in bronchoscopy market is segmented into cloud-based, on-premise, and hybrid.

Among these, the on-premise segment is anticipated to hold a leading market share. These artificial intelligence tools must work in real time inside the procedure room, integrated with imaging and navigation workflows where latency and reliability matter. Hospitals prefer on-premise deployment as it supports continuous availability, tighter integration with equipment, and easier compliance with clinical IT policies during live procedures. Highlighting these advantages, key companies are launching new products to expand their offerings in the segment. 

• For instance, in November 2024, GE HealthCare announced imaging innovations for OEC 3D to support interventional pulmonology workflows, including bronchoscopy use cases such as augmented fluoroscopy, reinforcing that key enabling systems are deployed directly in clinical suites.

Analysis by Technology  

Based on technology, the mrket is divided into computer vision, machine learning & deep learning, and others.

The machine learning and deep learning segment is projected to dominate the market. Wise applications of AI in bronchoscopy, such as navigation assistance, image enhancement, tom synthesis/3D reconstruction, and confirmation support, depend on models trained on large imaging datasets to improve accuracy and robustness. These systems handle variability in anatomy, breathing motion, and image quality, making ML/DL a crucial component behind computer vision outputs. Underscoring its essential applications, the technology is anticipated to dominate. Additionally, continuous upgrades and new product launches, particularly in this segment, reinforce robust growth. 

• For instance, in August 2025, Body Vision Medical announced a major LungVision platform upgrade that expanded access to AI Tomo, highlighting AI-driven image reconstruction used in bronchoscopy workflows. Such developments are expected to drive the segmental growth.

Analysis by Application

In terms of application, the market is divided into navigation & guidance, biopsy targeting & lesion detection, real-time anatomical mapping, performance assessment & training, and others

The navigation & guidance segment is anticipated to account for the largest market share. The applications overcome one of the challenging factors associated with traditional bronchoscopy. AI integration in bronchoscopy helps reliably reach small, peripheral lung nodules and reduces repeat procedures by better targeting. This application is directly tied to procedure success and throughput; providers prioritize navigation-enabled solutions over other applications. To meet this high demand, key companies are directing their resources toward research and development to support these navigation and guidelines applications. 

• For instance, in May 2024, Medtronic published outcomes from the VERITAS study for its fluoroscopic navigation platform, emphasizing real-time pathway adjustment and navigation to lung nodules. The study supported the dominance of the navigation/guidance use case. Such developments are expected to drive the segmental growth.

Analysis by End User

By end user, the market is divided into hospitals & ASCs, specialty clinics, academic & research institutes, and others.

Hospitals and ASCs are estimated to account for a leading market share. AI bronchoscopy is primarily used in these settings. Also, these settings are equipped with advanced imaging infrastructure, anesthesia support, and interventional pulmonology expertise. These sites also have stronger budgets and can build end-to-end lung nodule pathways. These factors increase utilization and ROI, prompting their significant market share. Furthermore, strategic collaboration among these solution providers and hospitals drives growth in the segment.  

• For instance, in May 2025, Independence Health System announced it is using J&J MedTech's MONARCH Platform to improve access to lung nodules for biopsy, demonstrating real-world hospital-led adoption. Such developments are expected to drive segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0 % of the global AI in bronchoscopy market in 2025.

The strong growth in North America is driven by the increasing prevalence of lung cancer and the growing preference for minimally invasive procedures. These factors also increase demand for AI-enabled navigation, targeting support, and real-time mapping during bronchoscopy. Hospitals in the region also have stronger access to advanced imaging and interventional pulmonology programs, robotic/navigational bronchoscopy, robust healthcare infrastructure, and software and service pull-through. Emphasizing these factors, key companies are also advancing their offerings through strategic partnerships and boosting market growth.

• For instance, in May 2025, Johnson & Johnson MedTech shared new clinical data supporting the MONARCH Platform for robotically-assisted bronchoscopy, reinforcing adoption momentum in the U.S.-led market. Such developments drive the market growth in the region.

Europe is expected to grow at a significant CAGR during the forecast period. The region's growth is driven by increased standardization in health systems to reduce variability. These factors have made AI-enabled bronchoscopy attractive for consistent navigation and targeting. Additionally, favorable government regulations and strategic partnerships expand distribution and access and reduce option friction, boosting the market growth.

• For example, in February 2026, FUJIFILM Healthcare Europe partnered with Lys Medical to strengthen bronchoscopy offerings in multiple European countries, for distribution supporting broader market rollout, thereby fueling market growth.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region's growth is driven by healthcare providers' increased investment in technologies that aid early lung cancer diagnosis. It also helps manage high patient volumes. As leading hospitals adopt these platforms, they create reference sites, accelerating broader regional adoption and training. This builds a pipeline of new program launches in emerging economies, rising demand for AI software upgrades, and integration services.

• For instance, in September 2025, Epworth Eastern introduced the Ion robotic bronchoscope, highlighting the adoption of advanced robotic bronchoscopy capability in Australia. Such developments are driving the region's growth.

Key Players covered

The global AI in bronchoscopy market is consolidated, with a few players capturing a significant market share.

The report includes the profiles of the following key players.

• Johnson & Johnson (U.S.)
• Medtronic (U.S.)
• Intuitive Surgical (U.S.)
• Veran Medical Technologies (U.S.)
• Body Vision Medical
• Noah Medical (U.S.)
• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (The Netherlands)
• Olympus Corporation (Japan)
• FUJIFILM Corporation (Japan)

Key Industry Developments

• January 2026: Optellum, a leader in AI-enabled lung cancer risk assessment, collaborated with the NHS to integrate its AI-driven lung cancer risk stratification with robotic-assisted bronchoscopy into the diagnostic pathway for lung cancer—the development aimed to help clinicians diagnose lung cancer earlier and minimize invasive procedures.
• October 2025: Thirona received clearance from the U.S. FDA for LungQ 4 Software, expanding AI-Powered capabilities in lung image analysis for the U.S. market.